Signaturefd, LLC Revance Therapeutics, Inc. Transaction History

Signaturefd, LLC

$5.2 Billion
Q3 2024

A detailed history of Signaturefd, LLC transactions in Revance Therapeutics, Inc. stock. As of the latest transaction made, Signaturefd, LLC holds 91 shares of RVNC stock, worth $233. This represents 0.0% of its overall portfolio holdings.

Number of Shares

Previous 103 11.65%

Holding current value

$233

Previous $0 NaN%

% of portfolio

0.0%

Previous 0.0%

14 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Oct 21, 2024	SELL	$2.57 - $2.57 $30 - $30	-12 Reduced 11.65%	91 $0
Q2 2024 Jul 29, 2024	SELL	$2.34 - $4.73 $1,071 - $2,166	-458 Reduced 81.64%	103 $0
Q1 2024 May 03, 2024	BUY	$4.65 - $9.31 $483 - $968	104 Added 22.76%	561 $2,000
Q4 2023 Jan 31, 2024	SELL	$5.81 - $11.2 $2,213 - $4,267	-381 Reduced 45.47%	457 $4,000
Q3 2023 Nov 03, 2023	SELL	$11.47 - $25.07 $6,365 - $13,913	-555 Reduced 39.84%	838 $9,000
Q1 2023 Apr 28, 2023	BUY	$18.36 - $35.27 $22,711 - $43,628	1,237 Added 792.95%	1,393 $44,000
Q4 2022 Jan 27, 2023	SELL	$18.32 - $30.66 $1,667 - $2,790	-91 Reduced 36.84%	156 $2,000
Q3 2022 Nov 08, 2022	BUY	$14.33 - $28.47 $1,977 - $3,928	138 Added 126.61%	247 $7,000
Q2 2022 Aug 10, 2022	BUY	$11.52 - $20.4 $276 - $489	24 Added 28.24%	109 $2,000
Q1 2022 May 02, 2022	SELL	$12.36 - $20.31 $3,399 - $5,585	-275 Reduced 76.39%	85 $2,000
Q4 2021 Jan 25, 2022	BUY	$12.46 - $27.87 $3,663 - $8,193	294 Added 445.45%	360 $6,000
Q3 2021 Oct 28, 2021	SELL	$25.78 - $33.21 $386 - $498	-15 Reduced 18.52%	66 $2,000
Q2 2021 Jul 26, 2021	BUY	$26.8 - $31.84 $402 - $477	15 Added 22.73%	81 $2,000
Q2 2019 Jul 31, 2019	BUY	$10.67 - $15.49 $704 - $1,022	66 New	66 $1,000

Others Institutions Holding RVNC

# of Institutions

234

Shares Held

82.8M

Call Options Held

680K

Put Options Held

896K

View Full List

About Revance Therapeutics, Inc.

Ticker RVNC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 82,305,696
Market Cap $212M
Description
Revance Therapeutics, Inc., a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company's lead drug candidate is DaxibotulinumtoxinA for injection, which has completed phase III clinical trials fo...

More about RVNC

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Signaturefd, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Signaturefd, LLC with notifications on news.

Account